Back to Journals » Biologics: Targets and Therapy » Volume 15

Biologics: Targets and Therapy


Archive: Volume 15, 2021

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population

Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, Elkayam O

Biologics: Targets and Therapy 2021, 15:463-470

Published Date: 18 November 2021

State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer

Basile D, Simionato F, Cappetta A, Garattini SK, Roviello G, Aprile G

Biologics: Targets and Therapy 2021, 15:451-462

Published Date: 3 November 2021

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers

Rizzo M, Giannatempo P, Porta C

Biologics: Targets and Therapy 2021, 15:441-450

Published Date: 1 November 2021

Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients

Santos-Moreno P, Martinez S, Ibatá L, Villarreal L, Rivero M, Rojas-Villarraga A

Biologics: Targets and Therapy 2021, 15:433-440

Published Date: 22 October 2021

Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia

Abuasab T, Rowe J, Tvito A

Biologics: Targets and Therapy 2021, 15:419-431

Published Date: 18 October 2021

Immunotherapeutic Advances for NSCLC

Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M

Biologics: Targets and Therapy 2021, 15:399-417

Published Date: 8 October 2021

Stem Cell Therapy for Burns: Story so Far

Abdul Kareem N, Aijaz A, Jeschke MG

Biologics: Targets and Therapy 2021, 15:379-397

Published Date: 31 August 2021

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG

Biologics: Targets and Therapy 2021, 15:363-374

Published Date: 27 August 2021

Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing

Mengstie MA, Wondimu BZ

Biologics: Targets and Therapy 2021, 15:353-361

Published Date: 21 August 2021

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Findeisen KE, Sewell J, Ostor AJK

Biologics: Targets and Therapy 2021, 15:343-352

Published Date: 12 August 2021

HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma

Xu Y, Zhijie H, Yu X, Li Z, Zheng L, Xu J

Biologics: Targets and Therapy 2021, 15:329-341

Published Date: 13 August 2021

Stem Cell Therapy for Retinal Degeneration: The Evidence to Date

Sharma A, Jaganathan BG

Biologics: Targets and Therapy 2021, 15:299-306

Published Date: 27 July 2021

Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval

Kurdi M, Butt NS, Baeesa S, Kuerban A, Maghrabi Y, Bardeesi A, Saeedi R, Alghamdi BS, Lary AI, Mohamed F, Hakamy S

Biologics: Targets and Therapy 2021, 15:289-297

Published Date: 24 July 2021

High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis

Elalouf O, Lidar M, Reitblat T, Zisman D, Balbir-Gurman A, Hakakian O, Mashiach T, Almog R, Elkayam O

Biologics: Targets and Therapy 2021, 15:279-287

Published Date: 20 July 2021

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

Elsbernd PM, Carter JL

Biologics: Targets and Therapy 2021, 15:255-263

Published Date: 30 June 2021

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease

Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang THW

Biologics: Targets and Therapy 2021, 15:237-245

Published Date: 16 June 2021

Recent Advances in the Treatment of Hemophilia: A Review

Marchesini E, Morfini M, Valentino L

Biologics: Targets and Therapy 2021, 15:221-235

Published Date: 15 June 2021

Monoclonal Antibody Therapies for High Risk Neuroblastoma

Furman WL

Biologics: Targets and Therapy 2021, 15:205-219

Published Date: 9 June 2021

Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer

Tiruneh G/Medhin M, Chekol Abebe E, Sisay T, Berhane N, Bekele Snr T, Asmamaw Dejenie T

Biologics: Targets and Therapy 2021, 15:199-204

Published Date: 31 May 2021

How Can We Engineer CAR T Cells to Overcome Resistance?

Glover M, Avraamides S, Maher J

Biologics: Targets and Therapy 2021, 15:175-198

Published Date: 19 May 2021

Antibody Therapies for Large B-Cell Lymphoma

Novo M, Santambrogio E, Frascione PMM, Rota-Scalabrini D, Vitolo U

Biologics: Targets and Therapy 2021, 15:153-174

Published Date: 18 May 2021

Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target

Chekol Abebe E, Mengie Ayele T, Tilahun Muche Z, Asmamaw Dejenie T

Biologics: Targets and Therapy 2021, 15:143-152

Published Date: 6 May 2021

Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review

Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, Marseglia GL

Biologics: Targets and Therapy 2021, 15:133-142

Published Date: 5 May 2021

Baculoviruses in Gene Therapy and Personalized Medicine

Schaly S, Ghebretatios M, Prakash S

Biologics: Targets and Therapy 2021, 15:115-132

Published Date: 28 April 2021

Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy

Hawkins ER, D'Souza RR, Klampatsa A

Biologics: Targets and Therapy 2021, 15:95-105

Published Date: 14 April 2021

Virus Neutralization by Human Intravenous Immunoglobulin Against Influenza Virus Subtypes A/H5 and A/H7

Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K

Biologics: Targets and Therapy 2021, 15:87-94

Published Date: 13 April 2021

Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon

O'Donnell KL, Marzi A

Biologics: Targets and Therapy 2021, 15:79-86

Published Date: 18 March 2021

Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature

Bounia CA, Theodoropoulou EN, Liossis SNC

Biologics: Targets and Therapy 2021, 15:61-66

Published Date: 17 March 2021

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis

Mohammadi R, Aryan A, Omrani MD, Ghaderian SMH, Fazeli Z

Biologics: Targets and Therapy 2021, 15:53-59

Published Date: 2 March 2021

Biologic Treatments of Psoriasis: An Update for the Clinician

Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J

Biologics: Targets and Therapy 2021, 15:39-51

Published Date: 16 February 2021

Convalescent Plasma for the Treatment of Severe COVID-19

Franchini M, Liumbruno GM

Biologics: Targets and Therapy 2021, 15:31-38

Published Date: 4 February 2021

Biologic Therapies for Giant Cell Arteritis

Harrington R, Al Nokhatha SA, Conway R

Biologics: Targets and Therapy 2021, 15:17-29

Published Date: 6 January 2021

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B

Biologics: Targets and Therapy 2021, 15:1-15

Published Date: 6 January 2021